n2y LLC has been acquired by The Riverside Company
n2y LLC, a leading developer of education curricula and teaching materials for K-12 students with special needs, has been sold to The Riverside Company.
Based in Huron, Ohio, n2y offers its products to teachers and school administrators through a cloud-based subscription platform. n2y’s core products include Unique Learning System, a standards-based special needs curriculum, news-2-you, a weekly current events newspaper and SymbolStix, a symbol-based language used in all of n2y’s learning materials. The company’s products improve student performance, teacher efficiency, school compliance and parent satisfaction by providing a highly customized and easy-to-use solution.
The Riverside Company is a global private equity firm focused on acquiring and investing in growing businesses valued at up to US$400 million. Since its founding in 1988, Riverside has invested in more than 420 transactions. The firm’s international portfolio includes more than 80 companies.
Oaklins DeSilva+Phillips, one of Oaklins’ TMT teams in New York, acted as co-advisor to n2y’s founders along with Citizens Financial Group’s M&A advisory team, formerly Western Reserve Partners LLC.
Chrissy Wostmann
President, n2y, LLC
Talk to the deal team
Related deals
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn more123.tv has been acquired by DVC Partners
123.tv, a digitally driven home and live shopping and e-commerce platform with a unique live auction format offered on its own TV channels and digital platforms, has been acquired by DVC Partners, a pan-European private equity firm.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more